Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Rimiducid
Synonyms
Therapy Description

Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Rimiducid AP1903|AP-1903|AP 1903 Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02743611 Phase I Rimiducid BPX-701 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Unknown status USA 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT03958656 Phase I Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Completed USA 0
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02792114 Phase I Rimiducid Mesothelin CAR-T cells Cyclophosphamide T-Cell Therapy for Advanced Breast Cancer Active, not recruiting USA 0
NCT04249947 Phase I P-PSMA-101 CAR-T cells Rimiducid P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting USA 0
NCT01744223 Phase Ib/II Rimiducid BPX-501 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting USA 0
NCT03741127 Phase I Rimiducid Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Enrolling by invitation USA 0
NCT02065869 Phase Ib/II BPX-501 Rimiducid Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Active, not recruiting 2
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT02487459 Phase I BPX-501 Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0


Additional content available in CKB BOOST